Opthea Limited (OPT)

Business: Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia.

IPO Date: 12-Apr-2012

MD, CEO & Exec. Director: Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D.

VP of Fin. & Company Sec.: Ms. Karen Adams CPA

Listing: NASDAQ: OPT

Country: Australia

Headquarters: South Yarra, VIC

Website: https://www.opthea.com

Market cap: $281.55 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-56.63 Mln

Cash: $88.27 Mln

Total Debt: $0.07 Mln

Insider's Holding: 0.00%

Liquidity: Low

52 Week range: $4.73 - 8.73

Shares outstanding: 43,992,400

10 Years Aggregate:

• CFO: $-130.17 Mln
• EBITDA: $-167.12 Mln
• Net Profit: $-115.36 Mln